• Announcements
  • Economy
  • Investment
  • IPOs
  • Weekly Markets
  • Products
  • Morninger
  • Eveninger
  • Industry
  • refer
  • 7824-003-757
  • Download App Get App
  • Contact
Flattrade Kosh Flattrade Kosh
Open Account
Flattrade Kosh Flattrade Kosh
Open Account
Flattrade Kosh Flattrade Kosh
Open Account
Flattrade Kosh
Open Account
Flattrade Kosh > Industry > Indian API industry to grow at 7-8% CAGR over 3-4 years, Govt. schemes to boost growth: ICRA
Industry

Indian API industry to grow at 7-8% CAGR over 3-4 years, Govt. schemes to boost growth: ICRA

Posted by Flattrade March 31, 2023
Share on
READ NEXT
Swiggy IPO

The domestic active pharmaceutical ingredient (API) industry is expected to grow at a CAGR of about 7%-8% over the next three to four years, according to ICRA rating agency. The estimated size of the industry is about Rs. 1,000-1,100 billion in CY2022, according to the rating agency

The growth is attributed to steady and stable rise in the formulations industry due to increasing geriatric population, growing prevalence of chronic diseases, and higher demand for contract manufacturing with global customers looking to diversify their supply chain dependence from China to alternative destinations.

“The Indian API industry has faced various headwinds such as rising input costs (raw materials, freight, and energy), forex volatility and supply chain disruptions due to the ongoing geopolitical disruptions, resulting in a sharp contraction of ~550-600 bps in the operating profit margins (OPM) of ICRA’s sample set to ~13.0% in FY2023E over ~18.7% in FY2021,” said Deepak Jotwani, Assistant Vice President & Sector Head – Corporate Ratings, ICRA.

Jotwani added that with the easing of supply chain disruptions and freight costs, and the expected stabilisation of raw material prices over the next few quarters, the OPM is likely to improve by 80-100 bps in FY2024.

Further, the Indian Government’s legislative support, the production linked incentive (PLI) scheme under its broader Atmanirbhar Bharat mission and bulk drugs parks scheme will boost the API industry’s growth significantly, helping to reduce the dependence on Chinese imports.

Jotwani said that the successful implementation of these schemes will reduce the dependence on China by ~25-30% in 4-5 years.”

Import Dependence On China

The past two years have been challenging for the Indian API manufacturers due to the dependence on China for imports. ICRA said that India imported about Rs 350 billion worth of APIs and bulk drugs in FY2022, accounting for approximately 35% of its total API requirement, of which China accounted for about 65-70% share.

Further, dependence on Chinese imports of APIs for certain essential medicines is as high as 80-100%, with almost the entire requirement of certain fermentation-based APIs like Penicillin and Erythromycin being sourced from China, ICRA added.

Due to the cost advantages of the Chinese API industry and the volatility in the prices of the APIs, domestic production of certain APIs is unviable for Indian manufacturers, leading to continued dependence on China.

Even when the APIs are manufactured locally, the key starting materials (KSMs) are still majorly sourced from China. The Chinese API industry accounts for about 40% of the global API requirement and is supported by benefits like higher economies of scale, subsidies and fiscal incentives offered by the Chinese government, and lower power, fuel, and borrowing costs.

Healthy Financial Metrics

ICRA’s sample set witnessed a healthy annual revenue growth of 15-18% over FY2021 and FY2022, with the trend expected to continue in FY2023 and FY2024. Meanwhile, inventory levels of API players further increased in FY2022 and FY2023 as companies tried to ensure production continuity while various geo-political disruptions impacted supply chains. However, the same is expected to ease to some extent over the near term.

With an increasing focus on domestic manufacturing of APIs and support by government through the PLI scheme, the API industry is expected to continue its capital expenditure investments. Nonetheless, the debt metrics (Total Debt/OPBDITA of 1.4-1.6 times) and return indicators (ROCE of 17-18%) of the sample set are expected to remain healthy over FY2023 and FY2024, helped by steady internal accrual generation and comfortable capital structure.

Open a Free Demat Account
Tags: active pharmaceutical ingredient API BSE COMMODITIES Demat Account Drugmaker drugs Earnings Economy Flattrade Forex Forex trading Market News Market Update Markets nifty nifty futures Nifty Today NSE Opening Bell options PHARMA Pharmaceuticals Pre Market sensex SENSEX Today Share Market Stock Market stocks Trading Account
Share on
Share on Facebook Share on Twitter Share on Pinterest Share on Email
Flattrade March 31, 2023
Previous Article markets Pre Market Report: Dalal Street may open lower; RIL, Hero MotoCorp, BEL, PNB in focus
Next Article Post Market Report: Dalal Street ends higher on buying spree; Bharat Dynamics, L&T and VA Tech Wabag in news

You Might Also Enjoy

Industry

Understanding NSE’s Guidelines for Client-Generated Algos: What Retail Investors Need to Know

May 7, 2025
Industry

Renewable Energy Sector: A surge in Investments and Growth

April 30, 2025
Eveninger

Benchmark indices ended lower; All the sectoral indices closed red; Broader indices tanked more than 2 percent

February 28, 2025
Morninger

Gift Nifty indicates a gap-down start for the Indian Stock indices; The US markets ended lower; The Asian markets also traded lower following the Wall Street.

February 28, 2025

Fortune Capital Services Private Ltd. SEBI Registration No. INZ000201438. Member Code for NSE: 14572 BSE:6524 MCX: 16765 and ICEX: 2010. CDSL DP ID: 12080300 SEBI Registration No.IN-DP-CDSL-729-2014. Registered Office: Kochar Technology Park, 6th Floor, SP-31-A, 1st Cross Road, Ambattur Industrial Estate, Ambattur, Chennai – 600 058. For any complaints pertaining to stock broking please write to [email protected] and for DP related to [email protected] Please ensure to read the Risk Disclosure Document carefully as prescribed by SEBI.

“Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances”

“Prevent unauthorised transactions in your account, update your mobile numbers/email IDs with your Stockbroker/Depository Participant. Receive information of your transactions directly from Exchange/Depository on your mobile/ email at the end of the day. Issued in the interest of investors”. As a business we do not give stock tips and have not authorized anyone to trade on behalf of others. If you find anyone claiming to be part of FLATTRADE and offering such services, please email to [email protected]. “KYC is one time exercise while dealing in securities markets – once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.” Dear Investor, if you are subscribing to an IPO, there is no need to issue a cheque. Please write the Bank account number and sign the IPO application form to authorize your bank to make payment in case of allotment. In case of non-allotment, the funds will remain in your bank account.


“Attention Investors 1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. 2.Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. 3. Pay 20% upfront margin of the transaction value to trade in cash market segment 4. Investors may please refer to the Exchange’s Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard. 5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month. Issued in the interest of Investors”

Disclaimer: ‘Investment in securities market are subject to market risks, read all the related documents carefully before investing’.

“Investment in Mutual Fund market are subject to market risk. There is no guaranteed or assured rate of return. Past Performance is not indication of future returns. Please read all related documents carefully before investing”.

“The securities quoted are exemplary and are not recommendatory”.


“Brokerage will not exceed the SEBI prescribed limit”.

Registered Office:

Fortune Capital Services Pvt Ltd
Kochar Technology Park, 6 th Floor,
1 st Cross Road, Ambattur Industrial Estate,
Ambattur, Chennai – 600058.

Company

  • Home
  • About
  • Kosh
  • IPO
  • Services
  • Pricing
  • List of Charges
  • Contact

Useful Links

  • Brokerage Calculator
  • Downloads
  • Margin Details
  • Fund Transfer
  • Knowledge Center
  • Refer & Earn
  • Investor Charter

Quick Contact

Support Number:
044-61329696 / 044-35019696

Support Email: [email protected]

Join our Telegram Channel for trading related activities and information.